University of Lille Nord de France-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2022

  1. Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

    Journal of Clinical Oncology